A snapshot of blood plasma proteomics in clinical response to atypical antipsychotics in schizophrenia – An exploratory study

ABSTRACT: Antipsychotics are usually the first option to treat schizophrenia; however, for a considerable fraction of patients, it lacks efficacy. Furthermore, there are no known biomarkers to indicate a treatment’s efficacy in a patient. Schizophrenia causes a large socioeconomic burden on countries along with an unquestionable impairment of the quality of life of patients and their relatives. As proteomics can identify, quantify, and characterize proteins in different conditions, it is a powerful tool to study complex diseases such as schizophrenia, also capable of revealing potential biomarkers. To improve treatment efficacy during the early stages of schizophrenia, a critical time period, molecular markers for a positive treatment response were sought. Blood plasma samples were collected in vivo from 26 patients before treatment with the atypical antipsychotics olanzapine and risperidone; they were then classified as good (GR) and poor (PR) responders. We were able to identify a potential panel of proteins that may predict a positive outcome to olanzapine and risperidone treatment. Although still exploratory, this data will assist in the development of personalized medicine strategies with potential clinical implementation

INSTRUMENT(S): Synapt MS

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Plasma

DISEASE(S): Paranoid Schizophrenia

SUBMITTER: Sheila Garcia-Rosa  

LAB HEAD: Daniel Martins-de-Souza

PROVIDER: PXD015213 | Pride | 2020-06-01

REPOSITORIES: Pride